intoxicant.wiki2catechol4school
Layout
Plant or preparation · Psychedelic

Psilocybin mushrooms

Also called Psilocybin, Magic Mushrooms, Shrooms, 4-PO-DMT

Original Wikipedia articleen.wikipedia.org/wiki/Psilocybin_mushroom revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Common dose · Oral10–25 mg Psilocybin PW
Onset20–45 minutes PW
Total6–8 hours PW
After-effects4–24 hours PW

Dosage

When sources disagree, both rows are shown as published. Nothing is averaged or merged.

Oral

SourceThresholdLightCommonStrongHeavy
PsychonautWiki2.5 mg Psilocybin PW2.5–10 mg Psilocybin PW10–25 mg Psilocybin PW25–50 mg Psilocybin PW50 mg Psilocybin+ PW
TripSit–0.5–1.5 g TS1.5–3.5 g TS3.5 g+ TS–

NOTE: Dosage ranges will vary between fungus strains. The doses given are for *dried* mushrooms, which are many times more potent by weight than those consumed when wet. Onset varies depending on dosage, common doses are normally felt within one hour. TS

TripSit dose text

TripSit's factsheet also states its doses as text.

Oral Light: 0.5-1.5g Common: 1.5-3.5g Strong: 3.5g+ | NOTE: Dosage ranges will vary between fungus strains. The doses given are for *dried* mushrooms, which are many times more potent by weight than those consumed when wet. TS

What dose are you on? (self-reported, unverified)
Read this first. These numbers come from anonymous visitors typing in a box. Nobody checks them. People misjudge, mistype, troll, or take untested products of unknown strength. They are not a dose guide and never override the sourced table above. They exist only so the sourced ranges can be compared with what people say they take. If you are deciding what to take, use the sourced table, start low, and read the risks section.
Running self-reports

No reports yet.

Reports are anonymous, one per browser per day per route. Counts under 20 are shown but marked as too few to mean anything. Until accounts launch, reports stay in this browser only.

Duration

Route · sourceOnsetCome-upPeakOffsetTotalAfter-effects
Oral · PsychonautWiki20–45 minutes PW1–1.5 hours PW2–2.5 hours[8] PW2.5–3.5 hours PW6–8 hours PW4–24 hours PW

TripSit factsheet

Onset
1 hours TS
Duration
4-6 hours TS
Aftereffects
1-24 hours TS

Mixing

Acute combinations: what happens when these are taken close together. Entries backed by a medical journal or agency are listed first.

Backed by medical journals

Awaiting sourcePeer-reviewed reports on acute combinations, from PubMed and the journals the harm reduction sites cite.

Other documented combinations

  • Unsafe Tramadol - Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures. PW
  • Unsafe Lithium - Lithium is commonly prescribed in the treatment of bipolar disorder; however, studies find it can significantly increase the risk of and seizures when combined to psychedelics. As a result, this combination should be strictly avoided. PW
  • Uncertain Amphetamines - Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences PW
  • Uncertain Cannabis: Cannabis can have an unexpectedly strong and unpredictable synergy with psilocybin mushrooms. While it is commonly used to intensify or prolong the mushrooms' effects, caution is highly advised as mixing these substances can significantly increase the risk of anxiety, paranoia, panic attacks, and psychosis. Anecdotal reports often describe the ingestion of cannabis as the triggering event for a bad trip or psychosis. Users are advised to start off with only a fraction (e.g. 1/4th - 1/3rd) of their typical cannabis dose and space out hits to avoid accidental over-intake.[9] PW
  • Uncertain Cocaine - Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences PW

TripSit combination chart

TripSit rates each pairing. Only pairings with a number carry a citation from TripSit. See the whole chart, with TripSit's note for every pairing.

Dangerous

lithium[10–14] TS

Unsafe

tramadol TS

Caution

amphetamines TScannabis TScocaine TS

Low Risk & Synergy

2c-t-x TS2c-x TS5-meo-xxt TSamt TSdextromethorphan TSdmt TSdox TSketamine TSlsd TSmaois TSmdma TSmescaline TSmxe TSnbomes TSnitrous TSpcp TS

Low Risk & No Synergy

caffeine TSopioids TS

Low Risk & Decrease

alcohol TSbenzodiazepines TSghb/gbl TSssris TS

Risks and toxicity

Numerous studies have found that psilocybin mushrooms are physiologically well-tolerated and has an extremely low toxicity relative to dose. There is no evidence for long-lasting effects on the brain or other organs and there are no documented deaths attributed to the direct effects of psilocybin mushrooms toxicity.[15] PW

However, it is worth noting that while they may not be capable of causing direct bodily toxicity or death, their use can still present serious hazards. PW

For example, they are capable of strongly impairing the user's judgment and attention span, which may promote erratic or dangerous behaviors. In extreme cases, the user may experience powerful delusions e.g. that they are actually inside of a dream and therefore physically invincible, or that they are being "chased by demons". This may prompt them to jump off of a building or run into oncoming traffic.[15] PW

Additionally, intense negative experiences and psychotic episodes (i.e. "bad trips") can cause lasting psychological trauma if not properly managed or treated afterward. This is particularly a concern in non-supervised settings or when heavy doses are used. PW

Finally, it should be noted that evidence of psilocybin mushrooms' effectiveness as a mental health treatment only applies to the controlled procedures used in clinical settings. They are not considered the entire treatment because the current evidence suggests they must be combined with professional psychotherapy to produce lasting effects. PW

Without the appropriate safeguards, attempts at self-medicating with psilocybin mushrooms may actually worsen mental health issues. PW⚠ PsychonautWiki itself has flagged this text: citation needed.

It is strongly advised to use harm reduction practices if using this substance. These include: PW

  • Taking the substance under the supervision of a tripsitter for one's first time or while experimenting with a higher dose PW
  • Starting off with a dose in the low-common range and monitoring for unusual reactions (e.g. mania, delusions) or sensitivity PW
  • Not exceeding the listed heavy dose. If heavy doses are required, a tolerance break is advised instead. Heavy doses greatly increase the risk of negative effects PW
  • Keeping a supply of benzodiazepines or antipsychotics (e.g. Seroquel) to abort the trip in the case of overwhelming anxiety or psychosis PW

Lethal dosage

The toxicity of psilocybin and psilocin is extremely low. In rats, the median lethal dose (LD₅₀) of psilocybin when administered orally is 280 milligrams per kilogram (mg/kg). PW

Psilocybin comprises approximately 1% of the weight of Psilocybe cubensis and so nearly 1.7 kilograms (3.7 lb) of dried mushrooms or 17 kilograms (37 lb) of fresh mushrooms would be required for a 60 kilogram (130 lb) person to reach the 280 mg/kg LD50 value of rats. PW

Based on the results of animal studies, the lethal dose of psilocybin has been extrapolated to be 6 grams, 1000 times greater than the effective dose of 6 milligrams. Unlike many highly prohibited substances, it is effectively impossible to physically overdose on. PW

Psychosis and mental disorder risk

Psilocybin mushrooms can exacerbate symptoms (e.g. delusions, mania, psychosis) of various mental disorders. Additionally, they can precipitate the early onset of schizophrenia in vulnerable individuals.[15] PW

Those with a personal or family history of mental disorders, particularly psychotic disorders like schizophrenia, should not use psilocybin mushrooms without consulting a qualified medical professional. PW

Dependence and abuse potential

Like other serotonergic psychedelics, psilocybin mushrooms have low abuse and no physical dependence potential.[16] PW

There are no literature reports of successful attempts to train animals to self-administer a serotonergic psychedelic, which is predictive of abuse liability, indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.[16] PW

Additionally, there is no human clinical evidence that psilocybin mushrooms causes addiction. Finally, there is virtually no withdrawal syndrome when chronic use of psilocybin mushrooms is stopped. PW

Tolerance to the effects of psilocybin builds almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). PW

Psilocybin exhibits cross-tolerance with all psychedelics, meaning that after the consumption of psilocybin all psychedelics will have a reduced effect. PW

Hallucinogen-perception persisting disorder (HPPD)

In rare cases, psilocybin mushrooms may trigger hallucinogen persisting perception disorder (HPPD) in some individuals. The cause is unclear; however, explanations in terms of psilocybin physically remaining in the body for months or years after consumption have been discounted by experimental evidence.[17] PW

Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action on brain chemistry, and varies according to the susceptibility of the individual to the disorder.[18] PW

Testing

Awaiting sourceReagent reactions and test kit guidance from a harm reduction testing service.

Effects

visual distortioncolor enhancementsense of connectedness with naturesense of well beingsense of wonder TS

Overview

Psilocybin mushrooms (also known as magic mushrooms, psychedelic mushrooms, and shrooms) are a family of psychoactive fungi that contain psilocybin, a psychedelic substance of the tryptamine class. The mechanism of action is not fully known, although binding activity at serotonin receptors is thought to be involved. PW

Fungi containing psilocybin, a prototypical psychedelic with similar effects to LSD, but with a shorter duration; also considered as being more confusing, introspective and entheogenic. Usually refers to psilocybe mushrooms rather than Amanitas, which have different effects. Are considered physically safe if properly identified, which should always be done by an expert.[1] TS

Psilocybin mushroom is a type of hallucinogenic mushroom and a polyphyletic informal group of fungi that contain the prodrug psilocybin, which is metabolised into the psychedelic compound psilocin following ingestion. Rather than referring to one single mushroom species, the term "psilocybin mushroom" refers to a broad group of fungi found across several genera. Other compounds such as baeocystin, norbaeocystin, aeruginascin, and β-carbolines may modulate effects. The most potent species are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from approximately a dozen other genera, including Panaeolus (including Copelandia), Inocybe, Pluteus, Gymnopilus, and Pholiotina.[2][3][4] WP⚠ The source has a footnote here that is not shown.

Amongst other cultural applications, psilocybin mushrooms are used as recreational drugs. While psilocybin mushrooms were used ritualistically in pre-Columbian Mexico for religious and divinatory purposes, their historical use elsewhere was rare and is often exaggerated. Such practices were suppressed after European colonization.[3][5] WP

Modern Western interest began in the mid-20th century with figures like R. Gordon Wasson and Timothy Leary popularizing their study and use. Legal status varies widely, with some U.S. states decriminalizing or allowing therapeutic use, and international treaties generally regulate only the active compounds, not the mushrooms themselves. Research has increasingly focused on therapeutic potential for depression, anxiety, and substance use disorders. Recent scientific literature has also expanded interest in the taxonomy, ecology, and neurobiology of psilocybin-containing fungi, not only their psychoactive properties.[6][7] WP

History

Early

The use of psilocybin mushrooms by humans in religious ceremonies dating back thousands of years is contested. Despite popular narratives portraying psychedelics as ancient, widespread, and primarily used by shamans for therapeutic healing, careful anthropological and historical research shows their traditional use was limited, recent, and culturally specific, with modern Western interpretations largely shaped by idealization, tourism, and ideological agendas. Reliable evidence shows that psilocybin mushrooms were used ritualistically in pre-Columbian Mexico but were otherwise rare, with most claims of ancient widespread use being exaggerated or misinterpreted.[5] WP

The Tassili Mushroom Figure was discovered in Tassili, Algeria has been argued to provide evidence of an early psilocybin-containing mushroom cult. 6,000-year-old pictographs discovered near the Spanish town of Villar del Humo illustrate several mushrooms that have been argued to be Psilocybe hispanica, a hallucinogenic species native to the area. Some scholars have also interpreted archaeological artifacts from Mexico and the so-called Mayan "mushroom stones" of Guatemala as evidence of ritual and ceremonial use of psychoactive mushrooms in the Mayan and Aztec cultures of Mesoamerica.[19][20] WP

The hallucinogenic species of the Psilocybe genus have a history of use among the native peoples of Mesoamerica for religious communion, divination, and healing, from pre-Columbian times to the present day. Aztecs and Mazatecs referred to psilocybin mushrooms as genius mushrooms, divinatory mushrooms, and wondrous mushrooms when translated into English. Bernardino de Sahagún reported the ritualistic use of teonanácatl by the Aztecs when he traveled to Central America after the expedition of Hernán Cortés.[21–24] WP

After the Spanish conquest, Catholic missionaries campaigned against the cultural tradition of the Aztecs, dismissing the Aztecs as idolaters, and the use of hallucinogenic plants and mushrooms, together with other pre-Christian traditions, was quickly suppressed. The Spanish believed the mushroom allowed the Aztecs and others to communicate with demons. Despite this history, the use of teonanácatl has persisted in some remote areas.[25][26] WP

A 2024 research paper identified Psilocybe maluti as a new described species from the Free State Province of South Africa and Lesotho in Southern Africa. Anecdotal reports suggests the mushroom was used spiritually and traditionally by Basotho healers, marking it the only documented instance of traditional hallucinogenic mushroom use in Africa and the earliest recorded reference to such practices in Sub-Saharan Africa.[27] WP

Modern

The first mention of hallucinogenic mushrooms in European medicinal literature was in the London Medical and Physical Journal in 1799. A man served Psilocybe semilanceata mushrooms he had picked for breakfast in London's Green Park to his family. The apothecary who treated them later described how the youngest child "was attacked with fits of immoderate laughter, nor could the threats of his father or mother refrain him."[28][29] WP

In 1955, Valentina Pavlovna Wasson and R. Gordon Wasson became the first known European Americans to actively participate in an indigenous mushroom ceremony. The Wassons did much to publicize their experience, even publishing an article on their experiences in Life on May 13, 1957. In 1956, Roger Heim identified the psychoactive mushroom the Wassons brought back from Mexico as Psilocybe, and in 1958, Albert Hofmann first identified psilocybin and psilocin as the active compounds in these mushrooms. The isolation of psilocybin was the culmination of a broader research effort that involved Indigenous collaborators, anthropologists, mycologists, universities, pharmaceutical laboratories, and intelligence-linked funding during the Cold War.[30–34] WP

Inspired by the Wassons' Life article, Timothy Leary traveled to Mexico to experience psilocybin mushrooms himself. When he returned to Harvard in 1960, he and Richard Alpert started the Harvard Psilocybin Project, promoting psychological and religious studies of psilocybin and other psychedelic drugs. Alpert and Leary sought to conduct research with psilocybin on prisoners in the 1960s, testing its effects on recidivism. This experiment reviewed the subjects six months later, and found that the recidivism rate had decreased beyond their expectation, below 40%. This, and another experiment administering psilocybin to graduate divinity students, showed controversy. Shortly after Leary and Alpert were dismissed from their jobs by Harvard in 1963, they turned their attention toward promoting the psychedelic experience to the nascent hippie counterculture.[35][36] WP

The popularization of entheogens by the Wassons, Leary, Terence McKenna, Robert Anton Wilson, and many others led to an explosion in the use of psilocybin mushrooms throughout the world. By the early 1970s, many psilocybin mushroom species were described from temperate North America, Europe, and Asia and were widely collected. Books describing methods of cultivating large quantities of Psilocybe cubensis were also published, for instance Psilocybin: Magic Mushroom Grower's Guide (1976) by Terence McKenna and Dennis McKenna. The availability of psilocybin mushrooms from wild and cultivated sources has made them one of the most widely used psychedelic drugs. WP

At present, psilocybin mushroom use has been reported among some groups spanning from central Mexico to Oaxaca, including groups of Nahua, Mixtecs, Mixe, Mazatecs, Zapotecs, and others. Psilocybin retreats such as MycoMeditations also exist in countries like Jamaica, where psilocybin mushrooms are legal. An important figure of mushroom usage in Mexico was María Sabina, who used native mushrooms, such as Psilocybe mexicana in her practice.[26][37] WP

Modern scientific and cultural interest in psilocybin mushrooms has continued to grow, especially because of renewed psychiatric and neuroscientific research in the 21st century.[38] WP

Pharmacology

Awaiting sourcePharmacology from Wikipedia and the journal papers it cites.

Chemistry

Awaiting sourceFormula, structure and identifiers from PubChem.

User reports

Erowid erowid.org

Listings

Erowid Experience Vault listing TS

Link as published on TripSit's factsheet.

Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Bluelight bluelight.org

Listings
Awaiting sourceTrip report threads and this substance's discussion forum.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Reddit reddit.com

Listings
Awaiting sourceTrip report posts and the relevant subreddits.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

References

  1. Other A study done on psilocybin leads psychiatrists to believe there are implications that it may help to treat ptsd
  2. Other How Long Do Drugs Stay in Your System? Everything You Want to Know. 2025-03-12
  3. Journal / agency Pepe M, Hesami M, de la Cerda KA, Perreault ML, Hsiang T, Jones AM. A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond. Biotechnol Adv. December 2023. doi:10.1016/j.biotechadv.2023.108247 · PMID 37659744
  4. Journal / agency Strauss, Dominique; Ghosh, Soumya; Murray, Zurika; Gryzenhout, Marieka. An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus. Frontiers in Forests and Global Change. 23 May 2022. doi:10.3389/ffgc.2022.813998
  5. Other Singh, Manvir. The ancient psychedelics myth: 'People tell tourists the stories they think are interesting for them'. 1 May 2025
  6. Other Psilocybin: A New Chapter in Mental Health Research
  7. Journal / agency Adeyinka, Dotun; Forsyth, Dayna; Currie, Suzanne; Faraone, Nicoletta. Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models. Frontiers in Systems Neuroscience. 2025-08-05. doi:10.3389/fnsys.2025.1585367 · PMID 40894380 · PMC12392120
  8. Journal / agency Pablo Mallaroni, Natasha L. Mason, Johannes T. Reckweg, Riccardo Paci, Sabrina Ritscher, Stefan W. Toennes, Eef L. Theunissen, Kim P.C. Kuypers, Johannes G. Ramaekers. Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition. Clinical Pharmacology and Therapeutics. May 2023. doi:10.1002/cpt.2958
  9. Harm reduction site TripSit Factsheets - Mushrooms
  10. Journal / agency Sandeep M Nayak, Natalie Gukasyan, Frederick S Barrett , Earth Erowid , Fire Erowid , Roland R Griffiths. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports
  11. Harm reduction site Erowid. Erowid Interactions
  12. Harm reduction site freshboi88. I Was Only on One Dose
  13. Harm reduction site YouWerentYouAnymore. Brought My Worst Thoughts to Life
  14. Journal / agency Otto Simonsson, Peper S. Hendricks, Richard Chambers, Walter Osika, Simon B. Goldberg. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
  15. Journal / agency Nichols, David E. Hallucinogens. Pharmacology & Therapeutics. 2004. doi:10.1016/j.pharmthera.2003.11.002
  16. Journal / agency Johnson, M. W., Griffiths, R. R., Hendricks, P. S., Henningfield, J. E. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. November 2018. doi:10.1016/j.neuropharm.2018.05.012
  17. Journal / agency Halpern, J. H.; Pope Jr, H. G. Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug and Alcohol Dependence. 2003. doi:10.1016/S0376-8716(02)00306-X · PMID 12609692
  18. Harm reduction site Lysergic acid diethylamide
  19. Journal / agency Samorini G. The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000-7000 BP). Integration. Zeitschrift für geistbewegende Pflanzen und Kultur. 1992
  20. Other Stamets P. Psilocybin Mushrooms of the World: An Identification Guide. 1996
  21. Other Abuse, National Institute on Drug. Hallucinogens DrugFacts. April 22, 2019
  22. Journal / agency F.J. Carod-Artal. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurología (English Edition). January 1, 2015. doi:10.1016/j.nrleng.2011.07.010 · PMID 21893367
  23. Other Stamets (1996), p. 7
  24. Other Hofmann A. LSD: My Problem Child. 1980
  25. Other Stamets (1996), p. 11
  26. Journal / agency Guzmán G. Hallucinogenic mushrooms in Mexico: An overview. Economic Botany. 2008. doi:10.1007/s12231-008-9033-8
  27. Journal / agency van der Merwe, B.; Rockefeller, A.; Kilian, A.; Clark, C.; Sethathi, M.; Moult, T.; Jacobs, K. A description of two novel Psilocybe species from southern Africa and some notes on African traditional hallucinogenic mushroom use. Mycologia. 2024-09-02. doi:10.1080/00275514.2024.2363137 · PMID 38953774
  28. Journal / agency Guzmán G. New Studies on Hallucinogenic Mushrooms: History, Diversity, and Applications in Psychiatry. Int J Med Mushrooms. 2015. doi:10.1615/intjmedmushrooms.v17.i11.10 · PMID 26853956
  29. Journal / agency Brande E. Mr. E. Brande, on a poisonous species of Agaric. The Medical and Physical Journal: Containing the Earliest Information on Subjects of Medicine, Surgery, Pharmacy, Chemistry, and Natural History. 1799. PMID 30490162 · PMC5659401
  30. Other Wasson RG. Seeking the magic mushroom. 1957
  31. Journal / agency Heim R. Notes préliminaires sur les agarics hallucinogènes du Mexique. Revue de Mycologie. 1957
  32. Journal / agency Hofmann A, Frey A, Ott H, Petrzilka T, Troxler F. Konstitutionsaufklärung und Synthese von Psilocybin. Cellular and Molecular Life Sciences. 1958. doi:10.1007/BF02160424 · PMID 13609599
  33. Journal / agency Hofmann A, Heim R, Brack A, Kobel H. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim. Experientia. 1958. doi:10.1007/BF02159243 · PMID 13537892
  34. Journal / agency Garcia de Teresa, Marcos. Selling the Priceless Mushroom: A History of Psilocybin Mushroom Trade in the Sierra Mazateca (Oaxaca). Journal of Illicit Economies and Development. 2 December 2022. doi:10.31389/jied.101
  35. Journal / agency Dr. Leary's Concord Prison Experiment: A 34-Year Follow-Up Study. Bulletin of the Multidisciplinary Association for Psychedelic Studies. 1999
  36. Other Lattin, Don. The Harvard Psychedelic Club: How Timothy Leary, Ram Dass, Huston Smith, and Andrew Weil killed the fifties and ushered in a new age for America. 2010
  37. Other Monaghan, John D.; Cohen, Jeffrey H. Ethnology. 2000
  38. Journal / agency Omidian, Hossein; Omidian, Alborz. The Emergence of Psilocybin in Psychiatry and Neuroscience. Pharmaceuticals. 9 April 2025. doi:10.3390/ph18040555 · PMID 40283990 · PMC12030455
  39. Other Unternehmensberatung, A. § 27 SMG (Suchtmittelgesetz), Unerlaubter Umgang mit Suchtgiften - JUSLINE Österreich
  40. Other All acording to articles (artigos) 2 and 33, Lei nº 11.343 of 23/8/2006, referring to numbers 160 and 161 of chart F2 (lista F2) of the Portaria SVS/MS nº 344 of 12/5/1998, last amended by Resolução de Diretoria Colegiada - RDC nº 835 of 13/12/2023, as of 29/2/2024. link 2
  41. Other Branch, L. S. Consolidated federal laws of Canada, Controlled Drugs and Substances Act. 2022
  42. Other Anlage I BtMG - Einzelnorm
  43. Other LEGGE 16 maggio 2014, n. 79
  44. Other Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
  45. Other Legilux
  46. Other Sidan kunde inte visas (#404) - Läkemedelsverket. 25 September 2013
  47. Other Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien
  48. Other Participation, E. Drugs Act 2005
  49. Journal / agency FDA - Controlled Substances Act. 2017
  50. Other Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020). Nov 3, 2020
  51. Other Brown, Jennifer. Colorado becomes second state to legalize "magic mushrooms". 10 November 2022
  52. Other Kenny, Andrew. A gray market emerges in Colorado after voters approved psychedelic substances. July 4, 2023
  53. Other Colorado Proposition 122, Decriminalization and Regulated Access Program for Certain Psychedelic Plants and Fungi Initiative (2022). Nov 8, 2022
  54. Other Frequently Asked Questions. Jul 2, 2022
  55. Other Psilocybin Drug Fact Sheet. April 21, 2020
  56. Other COURT OF APPEALS OF WISCONSIN PUBLISHED OPINION. June 21, 2007
  57. Other DMT – UN report. 2001-03-31

Text and values on this page are quoted from PsychonautWiki (CC BY-SA 4.0), Wikipedia (CC BY-SA 4.0), TripSit factsheets. Each value links to the exact revision it came from.